Neurocognitive, Emotional, and Quality of Life Outcomes in Survivors of Pediatric Acute Myeloid Leukemia: A Report from the Childhood Cancer Survivor Study (CCSS)

Background: Survivors of childhood Acute Myeloid Leukemia (AML) are vulnerable to medical late-effects of treatment; however, less is known about the psychological outcomes of AML survivors who do and do not receive bone marrow transplantation (BMT).

Objective: To evaluate neurocognitive, emotional and quality of life (QOL) outcomes in 5-year survivors of pediatric AML treated with BMT versus intensive chemotherapy (IC) relative to a sibling comparison group.

Methods: Survivors treated with BMT (N=186; 51% female; mean[SD] age = 30.2[7.3]; 50% received total body irradiation) or IC (N= 343; 51% female; age = 29.2[7.3]) who participated in the CCSS, were compared with siblings (N= 3289; 52% female; age = 32.7[8.8]) for neurocognitive deficits (CCSS Neurocognitive Questionnaire), emotional distress (Brief Symptom Inventory-18) and health-related QOL (Short-Form 36). Outcomes were dichotomized as impaired vs. non-impaired (impairment defined as scores >90th percentile for neurocognitive and emotional symptoms and <16th percentile for QOL). Multivariable Poisson regression models estimated relative risks (RRs), adjusted for age and sex, with robust variances to account for intra-family correlations.

Results: Compared to siblings, AML survivors were more likely to report impairment in ≥1 domain of neurocognitive (47.3% vs. 27.9%, RR 1.7, 95% CI= 1.4-2.0), emotional (18.6% vs. 12.6%, RR 1.5, 95% CI 1.2-1.8) and quality of life (47.3% vs. 32.3%, OR 1.85, 95% CI 1.39-2.46) function. Survivors had an increased RR compared to siblings for impairments in all neurocognitive domains: working memory (27.9% vs. 11.4%, RR 2.4, 95% CI= 1.7-3.3), organization (22.7% vs. 16.2%, RR 1.4, 95% CI 1.1-1.9), emotion regulation (17.4% vs. 8%, RR 2, 95% CI= 1.4-2.9) and task completion (30.8% vs 13.7%, RR 2.2, 95% CI= 1.6-2.9). Survivors treated with BMT were at higher risk for depression (14.6% vs. 8.0%, RR 1.9, 95% CI= 1.1-3.3) compared to IC. No other significant differences were observed.

Conclusion: AML survivors are at increased risk for neurocognitive impairments, emotional distress, and poorer quality of life; however, differences between the BMT and IC groups were minimal. As treatment for AML continues to rely on BMT for a subgroup of patients, our results are reassuring that improved oncology outcomes from BMT do not appear to come at the cost of increased neurocognitive or QOL impairments.

At 2578 out of 2600 Character limit